-
Once-Weekly Insulin Is Here. What Does It Mean for Your Patients?
What has felt like years in the making has finally arrived: a once-weekly insulin. This long-acting (basal) insulin, designed to be injected just once per week, has the potential to simplify long-term insulin therapy in a meaningful way. At first glance, it may not seem like a major shift. But for individuals taking insulin, and for those supporting them, reducing the burden of daily injections can make a real difference in self-care routines, "adherence", and ultimately long-term health outcomes. So what does this mean for you and your patients? Who might be a good fit, and how should you counsel…
-
Three Takeaways from the Colorado Food as Medicine Summit
Now in its third year, the Colorado Food Is Medicine Summit, hosted by Project Angel Heart and Kaiser Permanente, is a one-day event that brings together leaders, practitioners, and advocates to explore innovative programs, share research, and build sustainable solutions that place nutrition at the center of care. For me, it was a valuable opportunity to learn from experts in the field and to reconnect with clinicians, community health advocates, and organizations engaged in similar work, including many familiar faces. After a full day of conversation, here are three key takeaways that stood out to me and highlight how this…
-
How GLP-1s Are Reshaping Consumer Behavior
It’s been about a month since FNCE 2025 in Nashville, and I’m still sifting through my notes and revisiting the sessions I loved. One that stood out was the panel “The GLP-1 Effect: Understanding Consumer Behavior Shifts and Their Impact on Food, Nutrition, and Innovation.” The sheer scale of GLP-1 adoption and the depth of the data presented were striking. What made the session even more compelling was its interdisciplinary perspective, bringing together insights from industry leaders, physicians, RDs, and AI-generated consumer modeling. GLP-1 medications are reshaping metabolic health, culture, consumer expectations, and the future of the food landscape. Here…
-
Goodbye BMI? Why Body Composition Is Gaining Ground in Clinics
The rise of incretin-based therapies for obesity care, like Wegovy (semaglutide) and Zepbound (tirzepatide), has brought renewed attention to the risk of muscle atrophy that can accompany rapid weight loss. To better assess changes in skeletal muscle mass, clinicians are turning to body composition assessment tools to track progress over time. However, the ability to measure, interpret, and communicate changes in body composition is a skill most clinicians haven’t been formally trained in, leaving many feeling like it’s not a tool they can confidently use. I want to push back against that assumption and offer some basic principles to help…
